tg-1801
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 5, 2019 (NCT03804996)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04806035 | Phase 1 | Apr 23, 2021 | TG Therapeutics, Inc. |
| NCT03804996 | Phase 1 | Mar 5, 2019 | TG Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2019 |
1 organizations
Page 1 / 1